NPPA gives a deadline to manufacturers to submit availability data of 58 APIs

New Delhi: Following with earlier order where the apex drug price regulator, National Pharmaceutical Pricing Authority (NPPA) had asked manufacturers/importers of 58 key APIs to submit the available data related to their drug, the authority was recently seen giving a deadline to the companies for the same 

NPPA, Department of Pharmaceuticals recently issued an office memorandum in respect of all the importers of APIs, Manufacturers of formulations and APIs, Stockists asking to submit the information sought in the relevant form, duly signed and sealed by the authorised person before 11th March 2020 along with the soft copy in excel format of the same at the following email id manjesh.porwal@gov.in,dir-me-nppa@nic.in.

An active pharmaceutical ingredient is an ingredient in a pharmaceutical drug or pesticide that is biologically active.

Medical Dialogues has earlier reported that in the light of coronavirus outbreak worldwide, the apex drug regulator National Pharmaceutical Pricing Authority (NPPA) had identified 58 significant APIs for monitoring of their availability to prevent any shortage of drugs in India and to take preventive measures over illegal hoarding and black-marketing in the country.

For the same Rajesh K. Agrawal, Director (M&E), had recently directed all importers of APIs/manufacturers of formulations and APIs/ stockists to submit information about these drugs in the prescribed format.

Read also: Covid-19 Impact: NPPA Asks Drugmakers To Submit Availablility Data Of 58 APIs, Details

Previously, apex drug price regulator National Pharmaceutical Pricing Authority (NPPA) has written to all the states and union territories asking them to ensure that there is no shortage of drugs and APIs in their areas due to black marketing and hoarding

National Pharmaceutical Pricing Authority (NPPA) Chairman Shubhra Singh has recently written to the chief secretaries of all States and Union Territories to monitor the availability of APIs and drugs in the context of the outbreak of COVID-19 in China. WHO has since declared the situation as Global Health emergency.

Read also: Ensure That There Is No Hoarding, Blackmarketing Of Medicines: NPPA Chief Tells States On Covid-19 Outbreak